Researchers at The University of Texas Medical Branch at Galveston have successfully harnessed their Zika virus vaccine to target and kill brain cancer known as glioblastoma.
Children who experience some type of adverse event following initial immunization have a low rate of recurrent reactions to subsequent vaccinations, reports a study in The Pediatric Infectious Disease Journal, the official journal of The European Society for Paediatric Infectious Diseases. The journal is published in the Lippincott portfolio by Wolters Kluwer.
Primary care clinics experienced a significant decline in influenza vaccinations as the day progressed, researchers from Penn Medicine report in a new study published in JAMA Open Network. However, 'nudging' clinical staff to order vaccines using a behavioral economics technique known as 'active choice' may help curb some of that drop off, the study suggests. The study is the first to show how clinic appointment times can influence influenza vaccination rates.
Doctors and nurses are always grateful when they are given advance notice that a patient is about to seriously deteriorate (or 'crash,' to use today's clinical vernacular). Recent years have seen important advances towards this goal in the form of what are known as 'Clinical Early Warning Scores.'
Two new studies by scientists at Scripps Research are bringing Ebola virus's weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection--not only for Ebola virus, but for other closely related pathogens as well.
Studies show that primary reason for the measles outbreak, affecting several European countries, is the decline in vaccination coverage, for which mainly the 'spread of anti-scientific theories' can be blamed. However, a new study in the European Journal of Public Health shows that cuts in public health expenditure also play an important role, with measles, mumps, rubella (MMR) vaccination coverage decreasing 0.5 percentage points for each 1 percent expenditure cut
An intradermal vaccine equipped with an immune response-boosting adjuvant protected ferrets and humans against one of the more lethal strains of pandemic flu, researchers report. Their approach represents the first adjuvanted vaccine designed for intradermal delivery, which, because it does not require immunization expertise could one day be sent through the mail for self-administration.
Could we finally have a faster, more objective analytical tool to rapidly measure viral infectivity for vaccine development and production? Scientists and bioengineers at Thermo Fisher Scientific and LumaCyte believe we do. This peer reviewed work will be published on Sept. 12 in the prestigious journal, Vaccine, by Elsevier, detailing how LumaCyte's RadianceTM instrument, based on Laser Force Cytology (LFC), offers researchers the ability to rapidly analyze viral vaccines to speed development and production and ensure their effectiveness.
Around one percent of people infected with HIV produce antibodies that block most strains of the virus. These broadly acting antibodies provide the key to developing an effective vaccine against HIV. Researchers from the University of Zurich and the University Hospital Zurich have now shown that the genome of the HI virus is a decisive factor in determining which antibodies are formed.
Scientists at the University of Colorado Anschutz Medical Campus have discovered that disease-fighting T cells, elicited from vaccines, do not require glucose for their rapid reproduction, a finding with major implications for the development of immunotherapies for cancer patients.